Drug intelligence / Profile preview

RAP-641

Development stage: Unknown
Lead developer: Rapport Therapeutics
Modality: Small Molecules

Overview

RAP-641 is an investigational, clinical-stage small molecule agonist of the alpha-6 beta-4 nicotinic acetylcholine receptor (α6β4 nAChR), being developed by Rapport Therapeutics. It is designed as a non-opioid treatment for chronic pain and migraine. RAP-641 is generated from Rapport's receptor-associated protein (RAP) technology platform, which targets receptor-associated proteins to achieve neuroanatomical specificity and minimize off-target side effects. As of late 2026, RAP-641 is in Phase 1 clinical development, with preliminary results expected in the second half of 2027.

Targets

CHRNA6 (nAChR α6)CHRNB4 (nAChR β4 subunit)

Beyond the preview

Go deeper on RAP-641.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RAP-641.